ProCE Banner Series

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression

This 1.5-hour interactive live satellite symposium held in conjunction with the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will provide expert perspectives on therapies for patients with HR-positive/HER2-negative metastatic breast cancer harboring ESR1 or PIK3CA/AKT1/PTEN alterations following disease progression on endocrine therapy, including the biologic rationale for the use of these agents, clinical utility of circulating tumor DNA monitoring, and individualized treatment approaches for patients with HR-positive/HER2-negative advanced breast cancer harboring these alterations.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational activity is intended for medical oncologists, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with HR-positive/HER2-negative advanced breast cancer.

All Events

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression

Upcoming Events

May

31

2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave., Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in applying available clinical data on oral therapies to treatment selection and supportive care for patients with HR-positive/HER2-negative advanced breast cancer harboring ESR1 or PIK3CA/AKT1/PTEN alterations that progressed on or after first-line endocrine therapy. Secondary goals include improving patient engagement, aligning treatments to patient needs, and increasing patient satisfaction with care. 

Target Audience
This educational activity is intended for medical oncologists, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with HR-positive/HER2-negative advanced breast cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Educate patients and colleagues on the biologic rationale behind using oral SERDs and PI3K/AKT inhibitors in HR-positive/HER2-negative ABC progressing on a first-line CDK4/6 inhibitor plus ET
  • Evaluate the potential clinical use of ctDNA monitoring for early detection of disease progression in patients with HR-positive/HER2-negative ABC
  • Design individualized treatment plans for patients with HR-positive/HER2-negative ABC progressing on first-line endocrine therapy based on biomarker testing results, patient factors, clinical data, and expert recommendations
  • Appraise emerging data on novel oral SERDs and precision medicine approaches and their potential application to clinical practice for patients with HR-positive/HER2-negative ABC harboring ESR1 and/or PIK3CA/AKT/PTEN alterations
  • Collaborate with multidisciplinary colleagues, patients, and caregivers to minimize the risk of treatment-related toxicities in patients with progressive HR-positive/HER2-negative ABC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-152-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC.

CCO 2022

Supporters

Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.

AstraZeneca

Lilly

Stemline Therapeutics, Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191